 | Up a level |
Kuzin, Maxim; Schoretsanitis, Georgios; Haen, Ekkehard; Hiemke, Christoph; Stegmann, Benedikt; Gründer, Gerhard (2018). Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450 mediated metabolism of venlafaxine. Clinical pharmacokinetics, 57(6), pp. 729-737. Springer 10.1007/s40262-017-0591-8
Schoretsanitis, Georgios; de Leon, Jose; Haen, Ekkehard; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Paulzen, Michael (2018). Pharmacokinetics of risperidone in different application forms - comparing long-acting injectable and oral formulations. European neuropsychopharmacology, 28(1), pp. 130-137. Elsevier 10.1016/j.euroneuro.2017.11.009
Paulzen, Michael; Haen, Ekkehard; Hiemke, Christoph; Fay, Bianca; Unholzer, Sandra; Gründer, Gerhard; Schoretsanitis, Georgios (2017). Antidepressant polypharmacy and the potential of pharmacokinetic interactions: doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. Journal of Affective Disorders, 227, pp. 506-511. Elsevier 10.1016/j.jad.2017.11.046
Schoretsanitis, Georgios; Haen, Ekkehard; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Paulzen, Michael (2017). Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophrenia Research, 185, pp. 51-57. Elsevier 10.1016/j.schres.2016.12.016
Paulzen, Michael; Schoretsanitis, Georgios; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Schruers, Koen R J; Walther, Sebastian; Lammertz, Sarah E; Haen, Ekkehard (2017). Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Progress in neuro-psychopharmacology & biological psychiatry, 76, pp. 101-106. Elsevier 10.1016/j.pnpbp.2017.03.002
Paulzen, Michael; Haen, Ekkehard; Stegmann, Benedikt; Unterecker, Stefan; Hiemke, Christoph; Gründer, Gerhard; Schoretsanitis, Georgios (2017). Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. European archives of psychiatry and clinical neuroscience, 267(4), pp. 325-333. Springer 10.1007/s00406-016-0736-z
Paulzen, Michael; Haen, Ekkehard; Hiemke, Christoph; Stegmann, Benedikt; Lammerzt, Sarah; Gründer, Gerhard; Schoretsanitis, Georgios (2017). Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. British journal of clinical pharmacology, 83(8), pp. 1668-1675. Wiley-Blackwell 10.1111/bcp.13255
Schoretsanitis, Georgios; Haen, Ekkehard; Gründer, Gerhard; Stegmann, Benedikt; Schruers, Koen; Hiemke, Christoph; Lammertz, Sarah; Paulzen, Michael (2016). Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under Combined treatment. Journal of Clinical Psychopharmacology, 36(6), pp. 554-561. Lippincott Williams & Wilkins 10.1097/JCP.0000000000000601
Schoretsanitis, Georgios; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Schruers, Koen R J; Walther, Sebastian; Lammertz, Sarah E; Haen, Ekkehard; Paulzen, Michael (2016). Pharmacokinetic patterns of risperidone-associated adverse drug reactions. European journal of clinical pharmacology, 72(9), pp. 1091-1098. Springer 10.1007/s00228-016-2085-2
Paulzen, Michael; Haen, Ekkehard; Gründer, Gerhard; Lammertz, Sarah E; Stegmann, Benedikt; Schruers, Koen Rj; Walther, Sebastian; Schoretsanitis, Georgios (2016). Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. Journal of psychopharmacology, 30(8), pp. 803-809. Sage Publications 10.1177/0269881116650390
Paulzen, Michael; Haen, Ekkehard; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Lammertz, Sarah; Schoretsanitis, Georgios (2016). Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology, 73, pp. 9-15. Elsevier 10.1016/j.psyneuen.2016.07.009
Schoretsanitis, Georgios; Haen, Ekkehard; Hiemke, Christoph; Gründer, Gerhard; Stegmann, Benedikt; Schruers, Koen; Veselinovic, Tania; Lammertz, Sarah; Paulzen, Michael (2016). Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? International clinical psychopharmacology, 31(5), pp. 259-264. Wolters Kluwer Lippincott Williams & Wilkins 10.1097/YIC.0000000000000131
Schoretsanitis, Georgios; Haen, Ekkehard; Hiemke, Christoph; Gründer, Gerhard; Paulzen, Michael (2017). Pharmacokinetic differences for risperidone between genders. European neuropsychopharmacology, 27, S56-S57. Elsevier 10.1016/S0924-977X(17)30127-X
Schoretsanitis, Georgios; Eisenhardt, Sarah; Haen, Ekkehard; Lammertz, Sarah; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Paulzen, Michael (November 2016). Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients (Unpublished). In: WPA International 2016 Congress Cape Town.
Schoretsanitis, Georgios; Haen, Ekkehard; Lammertz, Sarah; Stegmann, Benedikt; Hiemke, Christoph; Kuzin, Maxim; Gründer, Gerhard; Paulzen, Michael (June 2016). Pharmacokinetic considerations of different dosing regimens in clozapine medicated patient. Pharmacopsychiatry, 49(03). Thieme 10.1055/s-0036-1582042
Schoretsanitis, Georgios; Haen, Ekkehard; Lammertz, Sarah; Stegmann, Benedikt; Hiemke, Christoph; Veselinovic, Tania; Gründer, Gerhard; Paulzen, Michael (June 2016). Pharmacokinetic considerations in coprescription of perazine in risperidone medicated patients. Pharmacopsychiatry, 49(03). Thieme 10.1055/s-0036-1582041
Kuzin, Maxim; Lammertz, Sarah; Stegmann, Benedikt; Haen, Ekkehard; Schoretsanitis, Georgios; Gründer, Gerhard; Paulzen, Michael (June 2016). Effects of proton pump inhibitors (PPI) on the metabolism of venlafaxine. Pharmacopsychiatry, 49(03). Thieme 10.1055/s-0036-1582053
